Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.

Abstract

Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions.

In this report, we highlight steps toward unlocking this potential, including the need for standardized, comprehensive data repositories as a way for addressing barriers to artificial intelligence learning, such as data heterogeneity and patient privacy.

COI Statement

M. Ruella reports grants from viTToria Biotherapeutics, AbClon, and Oxford Nanoimaging; nonfinancial support (equipment) from Beckman Coulter, LUMICKS, and CURIOX. M. Ruella serves on the Scientific Advisory Board of viTToria Bio, AbClon, Acera, and LUMICKS; receives consulting fees from GLG and Guidepoint; CAR T-related patents managed by the University of Pennsylvania and partly licensed to Novartis, Kite, and viTToria Bio. No disclosures were reported by the other authors.

References:

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature 2023;614:635–48.
Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, et al. . Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat Med 2022;28:1860–71.
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. . Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 2022;28:1848–59.
Kirouac DC, Zmurchok C, Deyati A, Sicherman J, Bond C, Zandstra PW. Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nat Biotechnol 2023;41:1606–17.
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, et al. . Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol 2023;41:1618–32.

Article info

Journal issue:

Volume: 6
Issue: 3

Doi:

10.1158/2643-3230.BCD-23-0240

More resources:

Silverchair Information Systems

Full Text Sources

Paid

Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.

Abstract

COI Statement

References:

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature 2023;614:635–48.
Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, et al. . Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat Med 2022;28:1860–71.
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. . Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 2022;28:1848–59.
Kirouac DC, Zmurchok C, Deyati A, Sicherman J, Bond C, Zandstra PW. Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nat Biotechnol 2023;41:1606–17.
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, et al. . Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol 2023;41:1618–32.